GSK » Topics » Coreg

This excerpt taken from the GSK 20-F filed Feb 29, 2008.
Coreg CR. URL/ Mutual had filed an ANDA with the FDA with a certification of invalidity, unenforceability and non-infringement of the patents covering the crystalline salt form and delayed release technology used for manufacturing that product which expire in 2023 and 2016, respectively. In January 2008, the USPTO reissued the Group’s patent on a method of use for administration of carvedilol with other therapeutic agents. The re-issued patent, which has been listed in the Orange Book, expires in 2016.

The Group’s action against URL/Mutual was amended to include a claim for infringement of the re-issued patent. FDA approval of URL/ Mutual’s ANDA is stayed until the earlier of June 2010 or resolution of the patent infringement action, but in no event can such approval issue prior to the expiration of the data exclusivity period in April 2010. The case is in its early stages.

This excerpt taken from the GSK 6-K filed Feb 7, 2008.
Coreg CR. URL/Mutual had filed an Abbreviated New Drug Application (ANDA) with the FDA with a certification of invalidity, unenforceability and non-infringement of the patents covering the crystalline salt form and delayed release technology used for manufacturing that product which expire in 2023 and 2016, respectively. FDA approval of that ANDA is stayed until the earlier of June 2010 or resolution of the patent infringement action but in no event can such approval issue prior to the expiration of the data exclusivity period in April 2010. The case is in its early stages.

In January 2008, the Group received a certification of invalidity, unenforceability and non-infringement from Barr Laboratories in respect of all three of its listed patents related to

This excerpt taken from the GSK 6-K filed Apr 25, 2007.
Coreg CR, a new simplified once daily, long-acting, cardiovascular treatment was launched in the USA on 22nd March for three cardiovascular conditions: hypertension, post-myocardial infarction left ventricular dysfunction and mild to severe heart failure.

This excerpt taken from the GSK 6-K filed Mar 22, 2007.
Coreg, Requip, Avodart and Boniva/Bonviva.

GSK continues to be the global leader in Respiratory with sales of its three key products, Seretide/Advair, Flixotide/Flovent and

This excerpt taken from the GSK 20-F filed Mar 2, 2007.
Coreg sales increased 38% to £773 million as it continued to benefit from its wide range of indications in heart disease. Zofran sales increased 8% to £679 million. A generic competitor to Zofran entered the market in November 2006.

Anti-bacterial sales declined 15% as a result of generic competition.

Europe
The discussion of individual market performance in the Europe region is on a turnover created basis.

Sales in Europe contributed 27% of pharmaceutical turnover and grew 1%, to over £5.5 billion, with strong sales from Seretide, Avandia/Avandamet and vaccines offsetting the impact of generic competition to a number of products and continued price cuts resulting from government healthcare reforms.

Markets which recorded good growth included Germany, the UK, Central and South/East Europe whilst growth in France, the Netherlands, Poland, Italy and Spain was adversely impacted by pricing and generics.

Major growth drivers were Seretide, GSK’s largest selling product in Europe, with growth of 10%, Avandia/Avandamet which grew 39%, and the vaccines franchise, up 20%. Sales of anti-virals grew 11% primarily due to government orders of Relenza as a measure in the event of a potential ‘flu pandemic.

Generic competition negatively impacted sales of Seroxat down 20%, Lamictal down 22%, Zofran down 14% and Imigran, down 18%. Sales of anti-bacterials decreased 12% due to a combination of a weaker ‘flu season than in 2005 and generic competition.

International
The International region reported year on year turnover growth of 6%. Strong growth in Japan, up 8% (despite the biennial price reductions), China/Hong Kong, up 7% and Latin America, up 10%, was partly offset by modest sales growth of 4% in Canada and 3% in Australia. The Canadian sales performance reflected generic competition for Imigran and Zofran whilst the Australian business was negatively impacted by Government pricing reforms and generic competition to Lamictal and Paxil.

The performance in Japan was driven by the sales of Paxil, up 15%, Serevent, up 16% and Anti-virals, up 8% and the full year impact of Zyrtec, an allergy product in-licenced from UCB in 2005. These were partially offset by declines in the older products Zantac and Zovirax. Flonase also declined due to a low pollen season.

Across all markets in International, the key products driving growth were Seretide, which grew 9% to record sales of £310 million, the Avandia range of products which grew 17% to £234 million, HIV products which grew 8% and the vaccines franchise, which recorded growth of 13% and achieved sales of £518 million.


 

 

GSK Annual Report 2006
34

Back to Contents

   
     REPORT OF THE DIRECTORS
   
  Business review
   
  Financial review 2006
  continued


   

Consumer Healthcare sales
An analysis of Consumer Healthcare sales is set out in the following table:

        Growth  
  2006   2005  


 
  £m   £m   CER%   £%  








 
OTC medicines 1,496   1,437   5   4  
     Analgesics 380   362   7   5  
     Dermatological 165   161   4   2  
     Gastro-intestinal 252   249   2   1  
     Respiratory tract 172   154   12   12  
     Smoking control 353   336   7   5  
     Natural wellness support 132   133     (1 )
Oral care 993   943   6   5  
Nutritional healthcare 658   619   7   6  








 
  3,147   2,999   6   5  








 

Consumer Healthcare sales grew 6% to £3.1 billion, with sales in International up 10% and Europe up 7%, performing well. Total sales in the USA were flat, with an improved performance in the fourth quarter, with sales up 7%.

OTC medicines
Over-the-counter medicine sales grew 5% to £1.5 billion with Panadol and smoking control performing well.

Oral care
Oral care sales grew 6% to £993 million. Sensodyne grew strongly, up 19% for the year to £257 million. Sales of Aquafresh were down 3% to £283 million.

Nutritional healthcare
Nutritional healthcare products sales grew 7% to £658 million. Lucozade, grew 14% to £301 million, and Horlicks, grew 6% to £156 million. Ribena sales were down 1% to £169 million.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki